AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

AbbVie (NYSE:ABBV) said it has received FDA approval for the intravenous antibiotic treatment Emblaveo, which was co-developed with Pfizer (NYSE:PFE). The FDA approved Emblaveo, a combination of ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI), including those caused by Gram-negative bacteria that represent a ...

The healthcare sector, too, has seen advances with AbbVie's EMBLAVEO™ gaining FDA approval for a combination antibiotic, and the European Medicines Agency recommending its arthritis treatment ...

Pfizer’s Emblaveo has been approved in the EU with ... including the US and Canada, where AbbVie holds rights. Use of the drug will likely be reserved for patients who have exhausted other ...

AbbVie is navigating significant shareholder ... This collaborative approach, alongside the FDA approval of innovative products like EMBLAVEO, has reinforced investor confidence.

The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the treatment of adults with complicated intra-abdominal infections (cIAI) with limited or no treatment ...

The healthcare sector, too, has seen advances with AbbVie's EMBLAVEO™ gaining FDA approval for a combination antibiotic, and the European Medicines Agency recommending its arthritis treatment, RINVOQ® ...